Charles River Laboratories International, Inc.
CRLCharles River Laboratories International, Inc. is a global research and development organization specializing in providing essential products and services for the pharmaceutical, biotechnology, and healthcare industries. Founded in 1947, the company offers early-stage contract research, preclinical and clinical support, and laboratory services to assist in the discovery, development, and manufacturing of new drugs and therapies. Its facilities and expertise enable clients to streamline drug development processes and meet regulatory requirements efficiently.
Company News
The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
Charles River Laboratories reported Q3 2025 earnings beating expectations, with revenue of $1.01 billion, but lowered full-year guidance and announced strategic asset sales, causing stock to decline.
The global cell-based assays market is projected to grow from USD 17.11 billion in 2023 to USD 35.34 billion by 2032, driven by increasing demand in drug discovery, toxicity testing, and advanced biotechnology research.
The global cell and gene therapy quality control market is projected to grow from $2.87 billion in 2025 to $22.81 billion by 2034, with a 25.74% CAGR. North America currently leads the market, while Asia Pacific is expected to witness the fastest growth, driven by technological advancements and increasing demand for personalized therapies.
